Chan Andrew C. 4

What Happened Andrew C. Chan, a director of Corvus Pharmaceuticals (CRVS), was granted a 30,000-share derivative award on April 23, 2026. The filing reports an acquisition at $0.00 per share (no upfront cash value reported) — this is an award/grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-04-23; reported on Form 4 filed 2026-04-27 (timely).
• Transaction type: Award/Grant of a derivative instrument (code A), 30,000 shares, reported price $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The underlying shares vest and become exercisable as to one-third of the shares on each annual anniversary beginning April 23, 2026, subject to continued service (3-year time-based vesting).
• No 10b5-1 plan, tax-withholding, or late-filing flags noted in this filing.

Context This was a compensation-related equity award to a director rather than a market purchase or sale. Because the award vests over time, the shares are not immediately available; future filings will disclose exercises or sales if/when they occur. Such grants are common for board compensation and should be viewed as part of executive/director pay rather than a direct buy/sell signal.